References

Unresolved reference

External reference

Unresolved reference

External reference

10.1378/chest.09-0360

10.1378/chest.09-0360 · External reference

Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies

10.1038/s41416-024-02857-7 · 2024 · External reference

Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence

10.3389/fendo.2024.1402583 · 2024 · External reference

10.2337/dci23-0100

10.2337/dci23-0100 · External reference

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

10.1172/jci.insight.140532 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

10.1007/s00125-022-05715-4 · 2022 · External reference

Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration

10.1155/jobe/3442754 · 2025 · External reference

Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis

10.17925/ee.2024.20.2.10 · 2024 · External reference

Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials

10.1016/j.dsx.2022.102640 · 2022 · External reference

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

10.1038/s41366-025-01859-6 · 2025 · External reference

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis

2023 · External reference

Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis

10.4239/wjd.v16.i4.101731 · 2025 · External reference

10.1056/nejmoa2206038

10.1056/nejmoa2206038 · External reference

10.1093/asj/sjad211

10.1093/asj/sjad211 · External reference

Resistance, Ineffectiveness, and Off-Label Use Related to Cephalosporins from the Reserve Group-A Pharmacovigilance Signal Detection Study on EudraVigilance Database

10.3390/ph19010155 · 2026 · External reference

Improving the Safety of Medicines in the European Union: From Signals to Action

10.1002/cpt.1678 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity

10.1001/jamanetworkopen.2025.40890 · 2025 · External reference

Unresolved reference

External reference

10.3389/fphar.2024.1397029

10.3389/fphar.2024.1397029 · External reference

10.5534/wjmh.250126

10.5534/wjmh.250126 · External reference

Unresolved reference

External reference

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program

10.1002/oby.24254 · 2025 · External reference

Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data

10.1016/j.obpill.2023.100072 · 2023 · External reference

10.1093/ije/dyz273

10.1093/ije/dyz273 · External reference

Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century

10.1016/j.eclinm.2019.10.001 · 2019 · External reference

10.1007/s00228-008-0494-6

10.1007/s00228-008-0494-6 · External reference

Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025)

2025 · External reference

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

10.1016/s0140-6736(21)02188-7 · 2021 · External reference

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

10.1016/s0140-6736(21)01443-4 · 2021 · External reference

10.1056/nejmoa2107519

10.1056/nejmoa2107519 · External reference

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

10.1038/s41591-023-02597-w · 2023 · External reference

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)01200-x · 2023 · External reference

10.1001/jama.2022.0078

10.1001/jama.2022.0078 · External reference

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

10.1016/s0140-6736(21)01324-6 · 2021 · External reference

Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database

10.1016/j.cegh.2024.101805 · 2024 · External reference

Unresolved reference

External reference

Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers

10.2337/cd22-0029 · 2023 · External reference

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups

10.3389/fphar.2024.1463657 · 2024 · External reference

Unresolved reference

External reference

Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates

10.1080/21556660.2019.1566137 · 2019 · External reference

10.1111/bcp.13098

10.1111/bcp.13098 · External reference

Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal

10.1186/2050-6511-14-16 · 2013 · External reference

10.1007/s13679-017-0262-y

10.1007/s13679-017-0262-y · External reference

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

10.1056/nejmoa2416394 · 2025 · External reference

Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data

10.14740/jocmr6231 · 2025 · External reference

Efficacy and safety of tirzepatide

10.1002/oby.24002 · 2024 · External reference

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

10.2196/publichealth.9282 · 2018 · External reference

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance

10.1007/s40801-018-0131-3 · 2018 · External reference

Patients’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review

10.1001/jamainternmed.2014.6016 · 2015 · External reference

10.1097/ms9.0000000000003801

10.1097/ms9.0000000000003801 · External reference

Unresolved reference

External reference

An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database

10.3390/biomedicines12051124 · 2024 · External reference

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

10.3390/ph16070994 · 2023 · External reference

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

10.1111/dom.13902 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol

10.1016/j.obpill.2025.100236 · 2026 · External reference